Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for Investors
The cash will help the biotech get to profitability.
Agios Pharmaceuticals
AGIO
AGIO
$46.70
$1.00
2.2%
BATS BZX Real Time Price as of December 13, 2019, 4:00 p.m. EST
View Interactive AGIO Charts
AGIOS PHARMACEUTICALS INC
News & Analysis: Agios Pharmaceuticals
Agios Pharmaceuticals Inc (AGIO) Q3 2019 Earnings Call Transcript
AGIO earnings call for the period ending September 30, 2019.
Agios Pharmaceuticals Inc (AGIO) Q2 2019 Earnings Call Transcript
AGIO earnings call for the period ending June 30, 2019.
Agios Pharmaceuticals Inc (AGIO) Q1 2019 Earnings Call Transcript
AGIO earnings call for the period ending March 31, 2019.
Agios Pharmaceuticals Inc (AGIO) Q4 2018 Earnings Conference Call Transcript
AGIO earnings call for the period ending December 31, 2018.
Could These Be the Next 2 Biotech Buyouts?
If GlaxoSmithKline's recent splurge signals a new round of acquisitions, these stocks could be next.
Why Alcoa, Merck, and Agios Pharmaceuticals Jumped Today
On a positive day for the market, these stocks outperformed. Find out why.
5 of the Most Hated Biotech Stocks on the Market: Are They Buys?
Short-sellers have piled on Agios, Insys, Intercept, Lexicon, and Myriad Genetics. But are they wrong?
3 Debt-Free Clinical-Stage Biotech Stocks That Are Swimming in Cash
Funding isn't a big concern for these three drug developers.
Why Agios Pharmaceuticals Sank 34.4% in 2016
It was a roller-coaster year for investors in the clinical-stage biotech. Here's a review of the year's key headlines that caused shares to drop.
